Latest Conference Articles

The new findings show worsened outcomes among particular comorbid patient groups, as well as minority patients.

A discussion on what the future of monitoring the rare disease may entail, and how COVID-19 interrupted in-person assessment earlier this year.

The combination therapy was linked to a record phase 3 progression-free survival rate among a subpopulation of patients with the rare cancer.

A discussion with a study author and longtime expert on improving monitoring of the rare disease.

The furthest-progressed gene-edited therapy for a genetic disease reported historic efficacy data in ongoing phase 1/2 trials.

The app improved pain, fatigue, and quality of life in children with the disease.

A study finds that children with cognitive or emotional deficits trended towards an increased healthcare utilization.

Patients with baseline PROMIS-57 scores worse than population norms reported clinically significant improvements in 6 of 8 domains at 12 months post-treatment.

Faster initiation of COVID-19 treatment is associated with better outcomes in patients with hematological malignancies.

Patients with acute myeloid leukemia or myelodysplastic syndromes are at especially increased risk for increased disease severity and death.

Investigators evaluated patients from 3 Chicago hospital systems and assessed risk factors associated with thrombosis.

Early assessment from an Australian team of investigators is targeting a pathway linked to hemoglobin expression.

High levels of fetal hemoglobin have previously been linked to the mitigation of morbidity and mortality of sickle cell anemia.

Those without prior exposure to venetoclax experienced the most benefit.

In a poster presented at ACG, investigators find a new patch test could help patients who are not responding to PPI therapy.

A uveitis specialist breaks down what occurs during the uveitis-dedicated event and comments on its importance.

Raymond Douglas, MD, PhD discusses how the COVID-19 pandemic has affected his clinical practice and potentially accelerated technological innovation as a whole.

A post-hoc analysis of the CANTREAT trial finds similar GA frequency, characteristics, and surface area between patients in treat-and-extend and once-monthly regimen cohorts.

There was very little difference found in visual acuity whether or not anti-VEGF treatments were used.

In data presented at AAO 2020, investigators test imaged guided intravitreal aflibercept injections for sight improvements.

A recent study presented at AAO 2020 reports that increased choroid vascular flow was noted in both small and large vessels in patients with non-vitrectomized eyes.

A new study from AAO 2020 is the first to show a significant association between peripapillary vessel density loss and progression of diabetic retinopathy.

A new IRIS registry analysis reports that many patients with geographic atrophy do not continue follow-up after initial visit or consultation.

RD surgery and scleral buckle appear to be preferred among ophthalmologists—but are linked to further necessary care in children.

Retinal nerve fiber layer density also appears to be influenced by presentation of both conditions.

Geeta Lalchandani-Lalwani, MD discusses the importance of early DR detection as well as findings from her study that suggest a need for more personalized therapies.

A new trial shows treatment-naive patients with nAMD have similar BCVA and safety outcomes with the biosimilar.

For patients with ETDRS DRSS scores of 47-53, about 40% experienced 2-step DR worsening by year 5.

Data show patients can decrease annual injections while retaining, if not improving, on BCVA scores over 104 weeks.

Lynn Hassman, MD, talks about a promising new technology that can optimize precision medicine in patients with uveitis.